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Summary The serum diagnostic value of the foeto-acinar pancreatic protein (FAP protein), an oncofoetal
pancreatic antigen, was tested in 201 patients. Of these, 112 suffered from malignant disease (57 patients had
pancreatic carcinoma and 55, extra-pancreatic malignancies) and 89 had benign disease (49 patients with
hepato-pancreato-biliary disease and 40 with other benign disease). FAP protein was measured by a
competitive radioimmunoassay. In this technique, the normal cut-off level was 10% inhibition. This was
deducted from values in 32 normal sera. FAP protein levels superior to 10% inhibition were found in 86% of
patients with pancreatic cancer, in 31% with non-pancreatic malignancy, in 69% with benign hepato-
pancreato-biliary disease and in 20% with other benign diseases. Accordingly, sensitivity of FAP protein for
pancreatic carcinoma was 86% and specificity, 66%. However, high FAP protein levels (>30% inhibition)
were almost exclusively seen in patients with pancreatic cancer. At this cut-off level, specificity increased to
95% but sensitivity decreased to 51%. Determination of the carbohydrate antigen CA19/9 was made in
parallel by a commercially available assay. At the cut-off level of 37uml- 1, CAl9/9 in our serum panel had a
sensitivity of 74% for pancreatic carcinoma and a specificity of 88%. In pancreatic cancer 55 out of 57
patients had elevated levels of either FAP protein or CA19/9 (sensitivity; 96%).
The incidence of carcinoma of the pancreas appears to be
increasing, but early diagnosis of this tumour is still difficult
(Trede, 1985), even after the introduction ofmodern procedures
such as endoscopic retrograde cholangiopancreatography
(ERCP), percutaneous transhepatic cholangiography (PTC),
computerized tomography (CT) and ultrasonographic
examination (Go et al., 1981; Moossa & Levin, 1981). Pan-
creatic cancer is usually far advanced by the time a patient
becomes symptomatic, therefore, a 'screening' serum test for
early detection would be of great clinical utility.
Pancreas specific antigens of an oncofoetal character were
first described in the Syrian golden hamster (Benedi ct al.,
1984) and later it was found that comparable antigens exist
in man (Escribano, et al., 1986). Using SDS-PAGE, the
principal antigens in man had a relative molecular weight of
60 kd and 110 kd. A murine monoclonal antibody recog-
nizing the 110 kd exclusively has recently been produced
(Escribano & Albers, 1986). This antigen was characterized
as a glycoprotein that binds to concanavalin A and is
specific for pancreatic acini. By immunohistology, this
protein exhibits an oncofoetal character, because maximal
expression occurs at 20 weeks gestational age and
gradually falls thereafter to remain at a low level in the adult
organ (Albers et al., 1987). Accordingly, the term foeto
acinar pancreatic (FAP protein) was adopted. Also by
histology, FAP protein was found to be strongly reexpressed
in pancreatic carcinoma mostly in peritumoural areas as well
as to a lower extent in chronic pancreatitis around inflam-
mation areas. Using nitrocellulose blots and competitive
RIA, FAP protein was shown-to be present in the serum of
the majority of patients with cancer of the pancreas and was
absent in nearly all other malignancies. However, FAP
protein elevation was also observed in benign diseases of the
pancreas (Albers & Escribano, 1986).
Carbohydrate antigen CAl9/9 is, so far, the most widely
used marker for pancreatic carcinoma, because, although it
is not absolutely specific for pancreatic cancer it reliably
distinguishes benign and malignant pathology (Ritts et al.,
1984; Tatsuta et al., 1985).
The purpose of the present study was to test the diagnostic
value of the FAP protein combined with CA19/9 in patients
with pancreatic disease and various other clinical control
groups.
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Materials and methods
Patients
Pathological and normal sera were collected from hospitals,
Amiens, Orleans, Villejuif (France) and Tokyo (Japan) and
stored at -30 C until used. Sera were classified according to
type of disease.
Group 0: This group comprised healthy individuals (n=32).
Gr-olup 1: These patients had benign non-hepato-pancreato-
biliary disease (n=40); 18 had peptic ulcer, 7 entero-colitis,
4 sigmoid polyp, 3 diabetes mellitus and 8 miscellaneous
diseases.
Group II. These patients had benign hepato-pancreato-
biliary disease (n =49). The diagnosis was established by
means of ERCP, CT scan, echography, laboratory findings
and/or laparotomy. Twenty-eight patients had chronic
pancreatitis, 14 liver cirrhosis, 7 biliary tract disease (3 with
common bile duct stones, 2 with gallbladder stones and 2
with dilatation of the common bile duct).
Gr-oup III: These patients had non-pancreatic malignant
disease without metastasis (n=55); 13 had gastric cancer, 9
colo-rectal, 8 ovarian, 9 breast, 7 lung, 3 hepatoma and 6
miscellaneous malignant diseases.
Group IV: Patients in this group had carcinoma of the
pancreas (n= 57). In 31, diagnosis was established histo-
logically. In 19, the diagnosis was obtained by operation and
in the remaining 7 it was made by means of ERCP, CT,
echography and laboratory findings. Twelve patients had
liver metastasis and 45 had no metastasis. Tumour stage was
not known but because most patients were symptomatic and
under treatment in hospitals they probably had advanced
disease as is frequently the case in this malignancy.
Monioclonal antihodi' (Mab J28)
BALB/c mice (8 week old) were given 6 s.c. monthly
injections of the ConA binding fraction from extracts of
17-25 week foetal pancreas. Extraction was made in the
presence of antiproteases (Escribano et al., 1986). In SDS-
PAGE, coomassie stained slabs this fraction consisted of
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-10 bands including the 1 10kd FAP protein. Immune
spleen cells were fused with SP2/0 cells (Buttin et al., 1976).
Hybridomas were selected by restricted specificity for foetal
pancreas in a nitrocellulose assay (Escribano et al., 1983;
Hawkes et al., 1982) and by immunohistology.
Mab J28 was then derived after 5 clonings and used as
ascitic fluid from BALB/c mice. This reagent is of IgGI
subclass and possesses high affinity for the 110 kd FAP
protein. Specificity for this protein was assessed by western
blot analysis of the semi purified foetal ConA+ fraction.
Recently, FAP protein was found in fluids obtained
preoperatively from patients having cyst and pseudocyst in
chronic pancreatic disorders. In these fluids FAP protein was
present as a single band (11Okd) on western blots whereas in
the foetal ConA+ fraction a doublet at 110kd and 100kd
was occasionally observed. Molecular microheterogeneity
could be attributable to variations in glycosylation.
Radiolabelling of the FAP protein
The FAP protein is not yet available in purified form. In our
first experiments the semipurified ConA+ foetal fraction
was used for radiolabelling purposes. This fraction proved to
be unstable after iodination whereas 1251 FAP protein in the
fluids of pancreatic cysts and pseudocysts conserved
molecular integrity and antigenic activity. One of these
fluids, (SP4), was selected because of its high content of
FAP protein (- 10% of the total protein of the fluid
corresponding to 100pgml-l FAP). SP4 fluid was radio-
labelled with 1251 using the chloramine T technique: 100jug1
total protein (50pl SP4) in 50p1 borate buffer 0.1M pH 8
and 250pCi 1 251 were used per experiment
(,Ci =3.7 x 104Bq). Radiolabelled SP4 fluid was mixed with
50pg cytochrome C and separated from free iodine in a
Sephadex G-25 prepacked column (PD-10 Column,
Pharmacia). A total of 1-1.5ml was collected having a
specific radioactivity of 6 x 104 cpm 1- 1 (inter-experiment
range; 5.8-6.2 x 104 cpm).
Radioimmunometric assay
Polypropylene beads (Oris, Saclay, France) were coated with
monoclonal antibody J28 as follows: J28 ascites, diluted
1/300 in PBS was allowed to react with solid beads for 18h
at 4"C. Afterwards, the beads were incubated in I % BSA for
3 h at 4°C in order to neutralize remaining active sites. They
were then washed with PBS, dried at 37°C and stored at
4'C.
Fixation of the 125I-SP4 was achieved as follows: Coated
beads were placed in 60 x 10mm flat-bottomed test tubes
(one bead per tube). Then, 300,u1 225I-SP4 serially diluted in
2% BSA (radioactivity range; 7.5 x 103-1.0 x 105 cpm) were
added. After 2h incubation at 4°C, beads were washed 3
times with 6ml PBS/Tween (1000/1) and the radioactivity
counted in a LKB gamma counter.
Inhbition assay
J28 coated beads were preincubated with samples to be
tested for 18 h. Then a constant amount of 125I-SP4 was
added and radioactivity was counted after 2 h incubation and
3 washes in PBS as described above. Background was
determined as the radioactivity fixed in beads coated with
2% BSA alone. The standard inhibition curve was
established using serial dilutions of cold SP4 in 2% BSA
(final volume 30Opl per bead). In the case of sera, beads
were pre-incubated with 100pl serum diluted to 300pl with
PBS.
Measurement of CA19/9
Sera were assayed with a solid phase radioimmunoassay
using a commercially available kit (ELSA, CA19/9 Kit, Oris,
Saclay, France). The upper limit of the normal range was
determined as 37 uml-1 (Del Villano et al., 1983). All sera in
our control normal group (group 0, n =32) had values below
this point.
Results
Validity of the RIA inhibition assayfor FAP protein
determination
In order to determine the amount of FAP protein present in
blood, a radioimmunoassay was developed. Radiolabelled
antigen in all experiments was pancreatic cystic fluid (SP4)
and FAP protein was evaluated by inhibition of the fixation
of this fluid to Mab J28 coated beads. Because of the
specificity of this monoclonal antibody only FAP protein
was measured in the molecular heterogeneous fluid.
Fixation of 125I-SP4 Fixation of 1211-SP4 to Mab J28
coated beads was linear when the amount of added 125I-SP4
varied between 7x 103 and 7 x 104 cpm. The fixation rate
was on average 8% of the added radioactivity (7.3%-9.6%).
For values of 1251I-SP4 >7 x 104 cpm, fixation reached a
plateau at 5.5 x 103 cpm.
Inhibition by cold pancreatic cystic fluid (SP4) SP4 was
diluted 1/20 in 2% BSA. Fifty percent inhibition was
obtained with lOpl of this dilution corresponding to 50ng
FAP. Maximal inhibition rate was 65%.
Inhibition in serum We tested 112 sera from malignant
disease, 89 from benign disease and 32 from healthy subjects.
All sera were analyzed in triplicate and values expressed as
mean cpm. In negative inhibition controls, serum was
replaced by 2% BSA. The inhibition rate was not dependent
on the total radioactivity added, using values between 3.5
and 4.5 x 104 cpm. In a typical experiment, when 3.8 x 104
cpm were added, the mean fixation value after incubation
with 2% BSA was 3,240 cpm and the background, 90 cpm.
Percentage inhibition was calculated as follows:
° Inhibitio__ (cpm of2% BSA)-(cpm of test serum) 100 00 (cpm of 2% BSA)-(cpm of background)
Determination of the cut-offpoint This was calculated from
values in normal sera (Group 0, n=32). The mean count for
this group was 3,266 cpm i.e. equal to control negative
inhibition using 2% BSA instead of serum. The s.d. was 166
cpm (range; 2,980-3,470 cpm). Twenty-two sera showed no
inhibition and 10 sera inhibited <8.3%. The cut-off point
was calculated from the mean value in normal sera.
Determination of cut-off point=3,266-2 x 166*
=2,934 (cpm) (* =s.d.)
This corresponds to an inhibition of 9.7%. Ten percent
inhibition was thus taken as the normal cut-off level.
FAP protein assay in serum Mean values of radioactivity
fixed to Mabs coated beads after inhibition by all sera,
inhibition range and significance are given in Table I to
show the liability of our assay.
Evaluation ofthe FAP protein and CA19/9 in benign disease
(Groups I and II)
Group I (n=40) FAP protein: Most of the patients (80.0%)
had FAP protein values within the normal range, and 20%
showed moderate elevation; i.e. in 7 cases inhibition was
<20% and one patient gave an inhibition of 26% (Table II).
This patient had a gastric ulcer suspected of penetrating the
pancreas.
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Table I Validity of the RIA inhibition test for FAP determination
in serum
FAP counts (cpm) FAP % inhibition
Group
(no. patients) Mean+s.d. Range Range (%)
Group 0 (32) 3,266+ 166a 2,980-3,550 0- 8.3
Group I (40) 3,115+259a 2,420-3,560 0-26.0
Group II (49) 2,722+440b 1,700-3,550 0-48.9
Group III (55) 3,095+287a 2,230-3,590 0-32.1
Group IV (57) 2,359+538 1,280-3,210 1.0-62.3
a(P<0.0001); b(p<0.005), Significance of difference from group
IV by two-tailed Wilcoxon test for independent samples.
Table II Values of FAP protein and CA19/9 in normal sera and
benign diseases
FAP(%) CAJ9/9 (uml-1)
Disease
(no. patients) <10 10-30 >30 <37 37-100 >100
Group 0 (32) 32 0 0 32 0 0
Group I (40) 32 8 0 39 1 0
Group II (49) 14 28 7 41 7 1
Chr. pancreatitis (28) 9 14 5 25 2 1
Liver cirrhosis (14) 3 10 1 11 3 0
Biliary disease (7) 2 4 1 5 2 0
<37 pml ' and that of the other one was 42 p ml (Table
II).
Group II (n=49) FAP protein: Fifteen sera (30.6%) were
FAP protein negative, 27 (55.1%) inhibited between 10 and
30% and 7 cases (14.3%) gave values >30% inhibition
(Table II). Of these, 5 had chronic pancreatitis, one had liver
cirrhosis with jaundice and one had choledocholithiasis. Of
the 5 cases of chronic pancreatitis, one patient had fibrosis
of the liver and two had a pseudocyst of the pancreas.
CA19/9 Forty-one cases (83.7%) had a normal CA19/9
level. In 7 patients (14.3%) 2 chronic pancreatitis, 3 liver
cirrhosis and 2 choledocholithasis, CA19/9 values were
between 37 and 100uml-1 (Table II). Finally only one
patient had values > 100uml-1. His condition was
diagnosed as chronic pancreatitis and the FAP protein level
was very high (48.9% inhibition).
Determination ofthe FAP protein and CA19/9 in malignant
disease (Groups III and IF)
Group III (n=55) FAP protein Thirty-eight (69.1%) had
normal values of FAP protein and 16 (29.1%) inhibited
between 10 and 30%. Only one case of lung cancer gave
32% inhibition (Table III).
Table III Values of FAP protein and CA 19/9 in malignant
diseases
FAP(%) CA19/9 (uml-1)
Cancer site
(no. patients) <10 10-30 >30 <37 37-100 >100
Stomach (13) 9 4 0 10 1 2
Colon-rectum (9) 6 3 0 8 1 0
Ovary (8) 7 1 0 7 0 1
Breast (9) 8 1 0 8 1 0
Lung (7) 3 3 1 5 0 2
Liver (3) 1 2 0 2 1 0
Miscellaneous (6) 4 2 0 3 1 2
Total (55) 38 16 1 43 5 7
Pancreas (57) 8 20 29 15 9 33
CAl9/9 In 43 (78.2%) CAI9/9 levels were <37uml-1, in 5
(9.1%) between 37 and 100uml-1 and in 7 (12.7%)
>100uml-1 (Table III). This included the lung cancer
patient giving 32% inhibition for FAP protein.
Group IV(n=57) FAPprotein Twenty-nine patients (50.9%)
had protein values >30% inhibition and 20 (35.1%)
inhibited between 10 and 30%. In 8 (14.0%) FAP protein
was within the normal range (Table III). No significant
differences between patients with widespread cancer (liver
metastasis n = 12) and no metastatic disease were observed.
CAJ9/9 In 15 patients (26.3%) CA19/9 levels were
<37uml-1 and 42 (73.7%) were >37uml-1. Thirty-three
patients (57.9%) had values >100 uml-1.
FAP protein distribution The percent of patients FAP
positive and negative in all groups is presented in Figure 1.
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Figure 1 Frequency of patients having normal (l, 0-10%
inhibition), moderate (o1 10-30%) and high (jC >30%) levels of
the FAP protein in serum. Group I: Benign non-hepato
pancreato-biliary diseases. Group II: Benign hepato-pancreato-
biliary diseases. Group III: Non-pancreatic malignant diseases.
Group IV: Pancreatic carcinoma.
Comparison of FAP protein and CA19/9 in benign and
malignant pancreatic disease (Groups II and IV)
Although high FAP protein values were found almost
exclusively in the case of pancreatic cancer in a significant
proportion of patients, separation of cancer of the pancreas
from hepato-pancreato-biliary disease was impossible on the
basis of FAP protein analyses alone. Thirty-five percent of
patients with pancreatic cancer and 55% of patients in group
II, possessed moderate FAP protein values (10-30%
inhibition).
However, high inhibition (>30%) was seen in 51 % of
pancreatic cancers and in only 14% of this benign disease
group. A good differential diagnosis was obtained in
combination with CA19/9. The level of CA19/9 was
>37uml-1 in 74% of patients with pancreatic carcinoma498 Y. FUJII et al.
and 16% patients in group II; values > 100uml-1 were
observed in only one patient (2%) in group II compared to
58% pancreatic carcinoma patients. Of the 35 patients (71%)
having benign diseases and FAP protein values over the
normal range, only 5 (14%) were CA19/9 positive (Figure 2).
Comparison ofFAP protein and CA19/9 in malignant disease
(Groups III and IV)
In cancer patients (n=112), the FAP protein assay had a
higher sensitivity (86%) than that of CA19/9 (74%) for
pancreatic cancer. Specificity of the FAP protein assay was
69% (cut-off point: 10% inhibition) and 98% (cut-off point:
30% inhibition). Compared to this, the specificity of CAl9/9
was 78% (cut-off point: 37uml-1) and 87% (cut-off point:
lOOuml-1).
Among the 15 pancreatic cancer patients (26%) negative
for CA19/9, 9 had moderately elevated FAP protein and 4,
high elevation. On the contrary in eight FAP protein-
negative cases, 6 were positive for CA19/9. As a result only 2
patients were negative for both markers i.e. in 55/57 (96%)
at least one marker was elevated (Figure 2).
Sensitivity andspecificity ofFAP protein and CA19/9for
pancreatic carcinoma
The assay parameters for all sera (n=233) for both markers
either alone or combined are summarized in Table IV. It can
be seen in particular that very high sensitivity (96%) is
obtained in the combined test.
Discussion
Earlier studies have shown that expression of FAP protein
rises strongly in pathological conditions of the pancreas, in
particular, neoplasia. Elevated production together with
necrosis of pancreatic tissue and/or dysfunction in the
metabolism of this protein could explain why it circulates in
the blood in the case of pancreatic pathology but not under
physiological conditions.
Table IV Diagnostic sensitivity and specificity (values are percentages)
FAP
(% inhibition) CA19/9 FAP (>10%) FAP (>30%)
(uml-) or or
>10 >30 >37 CAJ9/9 (>37) CAJ9/9 (>37)
Sensitivity 86 51 74 96 81
Specificity 66 95 88 61 85
Predictive value (+) 45 78 67 45 64
Predictive value (-) 94 86 91 98 93
Efficiency 71 85 85 70 84
Sensitivity=TP/TP+FN, Specificity =TN/TN+FP, Predictive value (+) =TP/TP+FP,
Predictive value (-) =TN/TN+FN, Efficiency =(TP+TN)/(TP+FP+TN+FN). TP =true
positive, FN=false negative, TN=true negative, FP=false positive.
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In the present study, we investigated the diagnostic value
of FAP protein in comparison with that of the carbohydrate
antigen CA19/9 and the combination of both markers. As in
previous work, FAP protein was determined here by
competition RIA using a normal cut-off level at 10%
inhibition instead of the former 5%. In pathology a second
cut-off point at 30% inhibition was considered because
values above this were found almost exclusively in pancreatic
carcinoma.
Levels greater than 10% inhibition were observed in 86%
of cancers of the pancreas, 69% of benign hepato-pancreato-
biliary diseases, 31% of other cancers and 20% of other
benign diseases. In the latter two groups all patients had
moderate FAP protein elevation (under 20% inhibition)
except two lung cancer patients (32% and 21% inhibition)
and one with gastric ulcer suspected of penetrating the
pancreas (26% inhibition).
By immunohistology, expression of FAP protein was
found to be confined to the exocrine pancreas. Other organs
including liver and biliary tissue, either normal or patho-
logical, were uniformly negative (Albers & Escribano, 1986).
This suggests that serum positivity in non-pancreatic disease
might be the result of alteration of the excretion of this
protein in the pancreas. At the cut-off point of 10%
inhibition, sensitivity of the FAP protein serum assay for
pancreatic pathology was 79% and specificity 80%; for
pancreatic carcinoma the corresponding values were 86%
and 66%, respectively. In previous reports (Albers &
Escribano, 1986; Escribano et al., 1987) sensitivity for cancer
of the pancreas was slightly superior (94%). The difference
can be explained by the choice of cut-off point and by the
fact that the sera in the two studies were not identical.
Sera from 29 patients with pancreatic carcinoma (51%), 5
with chronic pancreatitis (18%) and only one patient in each
of the groups liver cirrhosis, biliary disease and extra-
pancreatic cancer gave inhibition values in excess of 30%. At
this cut-off point specificity for cancer of the pancreas was
very high (95%) but sensitivity fell to 51% because about
50% of patients in both cancer of the pancreas and benign
hepato-pancreato-biliary diseases were in the 10-30%
inhibition range.
Our analysis of CAI9/9 again confirms the good differen-
tial diagnostic capacity of this marker in malignancy over
benign disease. In the latter group the cut-off point of
37uml-1 was exceeded in only 9 patients (10%). Of these, 8
were in the middle range (<100 uml -1). In malignancy, 74%
of pancreatic cancers and 22% of other cancers had elevated
levels of CAl9/9. Therefore, sensitivity for pancreatic cancer
was 74% and specificity, 88%. Specificity is higher than in
other reports probably because all patients with non-
pancreatic malignancies in this study had no metastases, but
sensitivity is in good concordance with previously reported
results (Gupta et al., 1985; Haglund et al., 1986). It remains
to be seen whether absence of metastasis in this group would
also affect the FAP protein specificity.
The combined assay of FAP protein and CA]9/9 provided
a test which was almost absolute for cancer of the pancreas.
Of the 35 patients positive for FAP protein in group II only
4 had elevated CAI9/9. Additionally 2 FAP protein negative
patients showed moderate elevation of this marker. One
patient with chronic pancreatitis had high levels of both
markers that could indicate suspicion of malignancy.
In cancer of the pancreas all except 2 patients revealed
elevation of one or other of the markers (sensitivity 96%).
The sensitivity of CEA combined with CA19/9 was reported
to be 88% (Gupta et al., 1985) or 85% (Haglund et al.,
1986) i.e. lower than in our study.
It is of interest that 13 pancreatic cancer patients with
normal CA19/9 values had elevated FAP protein against
only 8 FAP protein negative and CA19/9 positive. These
results show that FAP protein is not only more specific than
CA19/9 in discriminating amongst cancer sites (only one
extra-pancreatic cancer gave 31% inhibition in the FAP
protein assay against 6 with CA19/9 values >1O00 uml-1) but
that, furthermore, the overall sensitivity for pancreatic
carcinoma is higher.
A correlation between tumour stage of pancreatic carci-
noma and CA19/9 levels has been reported (Safi et al., 1986;
Tatsuta et al., 1985). In this study the stage of pancreatic
carcinoma was unknown. Studies in experimental carcino-
genesis of the pancreas (Escribano et al., 1985; Eriguchi
et al., 1987) have revealed that foetal pancreatic antigens
appear before microscopic tumours can be detected, sug-
gesting that they could serve as markers at a preclinical
stage. A follow up study is now required to correlate FAP
protein levels and extension of pancreatic tumour.
Adenocarcinoma of the exocrine pancreas is among the
most lethal and difficult to treat of all malignancies. The
survival of even curatively resected patients is still very poor.
The specificity of diagnostic techniques for early-stage
carcinoma of the pancreas is still disappointingly low. Early
detection would improve the chance of curative surgery. If
pancreatic disease were detected by a screening test, it might
not be difficult to diagnose even small cancers by modern
methods such as ERCP, PTC (Freeny & Ball, 1981), echo-
graphy lishi et al., 1986), CT scan (Sakahara et al., 1986),
angiography (Rosch & Keller, 1981), and other clinical and
laboratory findings. Therefore, the most important and
difficult problem is detection of pancreatic pathology in
asymptomatic patients. For this reason, a reliable and
specific screening test for pancreatic disease would be a
significant advance. Because of the high sensitivity of FAP
protein for pancreatic carcinoma and its excellent specificity
for pancreatic pathology, this new marker could be of poten-
tial utility in early clinical diagnosis. We are planning such a
test in a selected population.
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